CONMED (NYSE:CNMD – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.000-4.050 for the period, compared to the consensus estimate of 3.990. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. CONMED also updated its FY24 guidance to $4.00-4.05 EPS.
CONMED Stock Performance
Shares of CONMED stock traded up $0.58 during trading on Wednesday, hitting $65.26. 502,968 shares of the company’s stock traded hands, compared to its average volume of 487,169. The company has a debt-to-equity ratio of 1.09, a current ratio of 2.34 and a quick ratio of 1.13. CONMED has a 1 year low of $61.05 and a 1 year high of $117.27. The stock has a market capitalization of $2.01 billion, a P/E ratio of 25.00, a PEG ratio of 0.82 and a beta of 1.46. The business has a 50-day simple moving average of $69.55 and a 200-day simple moving average of $70.17.
CONMED (NYSE:CNMD – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $332.10 million for the quarter, compared to analysts’ expectations of $334.39 million. CONMED had a return on equity of 13.89% and a net margin of 7.73%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $0.83 earnings per share. As a group, analysts forecast that CONMED will post 3.99 EPS for the current year.
CONMED Dividend Announcement
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on CNMD shares. Stifel Nicolaus dropped their target price on CONMED from $88.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company dropped their target price on CONMED from $77.00 to $71.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Piper Sandler dropped their target price on CONMED from $95.00 to $80.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. StockNews.com raised CONMED from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of CONMED in a research note on Friday, October 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.80.
Get Our Latest Stock Report on CNMD
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
See Also
- Five stocks we like better than CONMED
- Investing in Construction Stocks
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What is the NASDAQ Stock Exchange?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Market Cap Calculator: How to Calculate Market Cap
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.